Table 1 Clinical characteristics of the ET patients grouped by driver mutation status.

From: Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia

 

Triple negative

JAK2 V617F

MPL exon 10

CALR exon 9

P value

 

TN vs JAK2

TN vs MPL

TN vs CALR

JAK2 vs MPL

JAK2 vs CALR

MPL vs CALR

 

N

23

94

9

52

        

Age median [IQR]

36.00 [27.00, 69.00]

59.00 [45.00, 69.00]

51.00 [43.00, 76.00]

47.00 [33.75, 57.25]

0.006

0.102

0.721

0.924

0.922

0.008

0.919

*

Sex male/female, n (%)

5/18 (21.7/78.3)

43/51 (45.7/54.3)

5/4 (55.6/44.4)

17/35 (32.7/67.3)

0.087

      

‡

WBC (×109/L) median [IQR]

8.1 [5.7, 10.0]

9.3 [8.0, 11.8]

7.6 [7.1, 10.9]

7.3 [6.2, 8.6]

<0.001

0.026

0.804

0.961

0.611

<0.001

0.505

*

Neut (%) mean (SD)

66.86 (10.83)

70.86 (8.07)

70.18 (8.61)

67.21 (7.29)

0.083

      

†

RBC (× 1012/L) median [IQR]

4.30 [4.16, 4.74]

4.78 [4.47, 5.12]

4.36 [4.28, 4.74]

4.55 [4.17, 4.76]

<0.001

0.002

0.897

0.716

0.340

0.008

0.998

*

Hb (g/dL) mean (SD)

13.01 (0.95)

14.32 (1.25)

13.53 (1.33)

13.44 (1.39)

<0.001

<0.001

0.714

0.543

0.278

0.001

0.997

†

Hct (%) mean (SD)

39.45 (2.85)

43.19 (3.50)

40.41 (3.36)

40.77 (3.93)

<0.001

<0.001

0.910

0.489

0.145

0.003

0.994

†

Platelet (×109/L) median [IQR]

1058 [721, 1313]

769 [678, 993]

1091 [720, 1522]

988 [809, 1227]

<0.001

0.034

0.996

0.988

0.263

0.001

0.996

*

EPO (mU/mL) median [IQR]

9.20 [6.70, 16.15]

10.60 [3.60, 14.00]

10.20 [6.50, 14.95]

12.15 [6.38, 19.05]

0.521

      

*

LDH (U/L) median [IQR]

192.00 [170.00, 237.00]

248.00 [212.00, 295.00]

355.50 [244.75, 405.00]

261.00 [222.00, 332.00]

0.001

0.003

0.133

0.004

0.443

0.763

0.635

*

Fe (μg/dL) mean (SD)

87.67 (27.16)

87.77 (31.47)

80.57 (18.79)

85.58 (23.70)

0.849

      

†

Ferritin (ng/mL) median [IQR]

64.50 [43.00, 102.15]

90.00 [52.25, 146.78]

124.00 [53.00, 157.00]

98.50 [31.50, 147.50]

0.800

      

*

MF grade 0/1, n (%)

18/0 (100.0/0.0)

58/27 (68.2/31.8)

5/3 (62.5/37.5)

29/12 (70.7/29.3)

0.045

0.032

0.034

0.061

1.000

1.000

1.000

‡

Abnormal karyotype Fav/Unfav/VH, n (%)

21/1/0 (95.5/4.5/0.0)

81/9/0 (90.0/10.0/0.0)

9/0/0 (100.0/0.0/0.0)

44/5/0 (89.8/10.2/0.0)

0.650

      

‡

Thrombotic events presentation, n (%)

0/23 (0.0)

25/94 (26.6)

0/9 (0.0)

7/52 (13.5)

0.006

0.032

1.000

0.388

0.453

0.397

1.000

‡

IPSET-thrombosis score low/Int/high, n (%)

18/5/0 (78.3/21.7/0.0)

0/31/63 (0.0/33.0/67.0)

9/0/0 (100.0/0.0/0.0)

44/5/3 (84.6/9.6/5.8)

–

–

–

–

–

–

–

 
  1. IQR interquartile range, Fav Favorable, Unfav Unfavorable, VH Very High, Int Intermediate.
  2. *Kruskal–Wallis test/Steel–Dwass test, †One-way ANOVA/Tukey's HSD test, ‡Chi-square test/chi-square test with Bonferroni correction.
  3. P-values in bold indicate significance (< 0.05).